# NP202 for Treatment of Post -STEMI Left Ventricular Systolic Dysfunction

> **NCT02557217** · PHASE2 · UNKNOWN · sponsor: **Armaron Bio Pty Ltd** · enrollment: 120 (estimated)

## Conditions studied

- ST Elevation Myocardial Infarction

## Interventions

- **DRUG:** NP202
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02557217
- **Lead sponsor:** Armaron Bio Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-10
- **Primary completion:** 2017-12
- **Final completion:** 2018-02
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2017-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02557217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02557217, "NP202 for Treatment of Post -STEMI Left Ventricular Systolic Dysfunction". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02557217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*